For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...
Complement‑targeted therapeutics continue to expand, with C3, C5, and alternative‑pathway inhibitors advancing through clinical pipelines. Creative Biolabs’ complement assay kit suite spans the ...
Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES ...